Analyst Note
| Alex Morozov, CFA |We are maintaining our fair value estimate of $306 for narrow-moat Becton, Dickinson following second-quarter earnings. We currently view shares as undervalued.
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
Capital Allocation
PREMIUM
We are maintaining our fair value estimate of $306 for narrow-moat Becton, Dickinson following second-quarter earnings. We currently view shares as undervalued.
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.